Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1432-0584
    Keywords: Key words LW/SO cell line ; Stem cell phenotype ; Stem cell commitment ; Lineage infidelity ; Lineage promiscuity ; CD4 ; CD25 ; CD34
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  We report our observations with the cell line LW/SO, which was recently derived from the bone marrow of a patient with acute myeloid leukemia. Based on the morphological and histochemical examination, the leukemic cells were classified primarily as FAB type M4. However, 2 years later, in relapse, the cells changed their morphology and were hence specified as FAB type M2 (slightly positive for acid phosphatase and Sudan black). The cells established have now been in culture for approximately 11 months and display nearly 100% CD4/5/7/15/25/71/120a, b at varying densities. Some of them spontaneously and reversibly become either CD34+/38– or CD34–/38+, yet the majority of the cells remain negative for both. All attempts to separate the cells with a distinct phenotype by limiting dilution or sorting through a flow cytometer failed repeatedly. The subsets, enriched up to 98% (regardless of their primary immunophenotype CD34–/38–, CD34+/38–, or CD34–/38+), soon displayed a phenotypical constellation similar to that before sorting. The ratio of CD34– to CD34+ seems to be influenced by the cell density: The greater the cell-to-cell contact, the lower the percentage of CD34-expressing cells. Some of the cells apparently differentiate into T-cell phenotype and acquire CD3 and T-cell receptor (TCR) α/β molecules. While the quantity of CD34-expressing cells significantly increased in the presence of dexamethasone (10–7 M), and some of them additionally acquired CD33 antigen, the percentage of CD3-positive cells was enhanced by adding 1% DMSO in medium. In contrast, cytokines such as IL-1, IL-2, IL-3, IL-4, IL-6, G-CSF, GM-CSF, or SCF (c-kit ligand) altered neither the proliferation capacity nor the phenotypical constellation of LW/SO cells (each tested alone). Although normal karyotype was obtained from the bone marrow cells, the LW/SO cells revealed a homogeneous chromosomal composition of 45, X,–X, der(9) inv(9) (p12q13) del(9) (p22?). These data suggested that LW/SO cells might be the leukemic counterpart of putative pre-CD34-positive progenitors. In order to substantiate this assumption, we analyzed the expression of other so-called T-cell markers on CD34+ cells from peripheral blood stem cell aphereses of five patients who later underwent high-dose chemotherapy and subsequent stem cell retransfusion. These data clearly revealed that a considerable amount of CD34+ hematopoietic progenitors co-express CD2/4/(5)/(7)/25 at an early stage of differentiation, and support the notion that CD34-negative LW/SO cells with the surface markers CD4/5/7/25 are probably phenotypical representatives of pluripotent stem cell. Hence, not all CD34-negative populations with so-called T-cell surface markers should be considered T-cells; some may constitute the ancestor of CD34 antigen-expressing progenitors.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-1440
    Keywords: Corynebacterium parvum ; Chemotherapy ; Metastatic breast cancer ; Corynebacterium parvum ; Chemotherapie ; metastasierendes Mammakarzinom
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Seit September 1975 haben wir 156 Patientinnen mit metastasierenden Mammakarzinomen in eine prospektive multizentrische Studie aufgenommen. Alle Patientinnen erhielten 6 Zyklen Vincristin, Adriamycin und Cyclophosphamid (VAC) und anschließend weiterhin monatlich einmal 5-Fluorouracil, Methotrexat und Cyclophosphamid (FMC), bis eine Tumorprogression dokumentiert wurde. Auf Grund randomisierter Zuweisung erhielt etwa die Hälfte der Patientinnen zusätzlich subkutan Injektionen von Corynebacterium parvum jeweils am Tag 1 eines Chemotherapiezyklus (VAC/FMC). Bei den 150 auswertbaren Patientinnen fanden sich 33 von 76 (45%) bzw. 36 von 74 (49%) komplette oder partielle Remissionen unter Chemotherapie ohne bzw. mit Zusatz von Corynebacterium parvum. Die Kaplan-Maier-Kurven für die Dauer der Remissionen und des Überlebens waren bei beiden Kollektiven fast identisch (mediane Remissionsdauer 14,5 bzw. 12,1 Monate und mediane Überlebenszeit 22,2 bzw. 21,1 Monate). Die hämatologischen und gastrointestinalen Nebenwirkungen waren bei beiden Gruppen ebenfalls ähnlich. Auffällig war jedoch, daß 19 von 74 (26%) Patientinnen als Folge der wiederholten subkutanen Injektionen von Corynebacterium parvum Hautulcera entwickelten. Diese Patientinnen zeigten die längste Überlebenszeit (p=0.002, log rank test). Diese Ergebnisse lassen vermuten, daß eine unspezifische Immunstimulation mit Corynebacterium parvum am Tag 1 der heute üblichen Polychemotherapie den meisten Patientinnen mit metastasierenden Mammakarzinomen nichts nützt, sondern eine „immunreaktive“ Untergruppe mit gesteigerter lokaler Toxizität und Überlebenszeit selektioniert.
    Notes: Summary A total of 156 patients with metastatic breast cancer were entered into a prospective multicenter trial in September 1975. All patients were treated monthly with vincristine, adriamycin and cyclophosphamide (VAC) six times, followed by 5-fluorouracil, methotrexate and cyclophosphamide (FMC) until progression was documented. By random assignment, the patients received 5 mg/m2 Corynebacterium parvum (CP) subcutaneously on day 1, in addition to VAC/FMC. Of the 150 evaluable patients, 33 of 76 (45%) and 36 of 74 (49%) had complete or partial response to VAC/FMC plus CP, respectively. The Kaplan-Maier curves of duration of remission and survival were almost identical (medians 14.5 vs 12.1 months and 22.2 vs 21.1 months, respectively). The hematologic and gastrointestinal toxicity were also similar in the two study groups. However, 19 of 74 (26%) patients developed skin ulcers after repeated injections of CP. These patients showed prolonged survival (P=0.002, log rank test). These results suggest that adding nonspecific immunostimulation with CP to currently available chemotherapy on day 1 is of no benefit to most patients with metastatic breast cancer, but may select an ‘immunoreactive’ subgroup with increased local toxicity and survival.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...